<DOC>
	<DOCNO>NCT00127803</DOCNO>
	<brief_summary>The purpose study determine safety tolerability modify C. difficile vaccine 3 dose level compare placebo control administer via intramuscular injection healthy adult age 18-55 year age .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Study Clostridium Difficile Toxoid Vaccine Healthy Adult Volunteers</brief_title>
	<detailed_description>Clostridium difficile lead infectious cause nosocomial diarrhea develop country . Hospital outbreaks Clostridium difficile-associated diarrhea ( CDAD ) associate substantial patient morbidity mortality . Conventional therapy antibiotic often result secondary infection resistant organisms clinical relapse discontinuation antimicrobial course . New strategy need limit impact opportunistic pathogen . Considerable evidence exist immunity C. difficile toxin may effective control CDAD . 48 subject enrol receive one three dose level modify C difficile vaccine placebo administer 3-dose schedule . The study consist 30-day screening period , 70-day treatment period , one follow-up phone interview 2 month last vaccination , one follow-up clinic visit 6 month last vaccination .</detailed_description>
	<mesh_term>Clostridium Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male female , 1855 year ( inclusive ) In good general health Clinical lab test within normal range Nonpregnant female subject Able willing participate duration study must participate experimental study least 60 day receive last dose study vaccine Evidence C. difficile infection Evidence previous antibioticassociated diarrhea Active inactive inflammatory bowel disease , irritable colon syndrome , chronic abdominal pain chronic diarrhea History malignancy within 5 year History anaphylaxis , asthma severe vaccine severe allergic drug reaction Known suspect history immunodeficiency ; Active inactive immunemediated inflammatory disease ; Pregnant lactate female subject ; History drug alcohol abuse disorder ; Serology positive HIV , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) Receipt antibiotic therapy investigational drug within prior 30 day Blood organ donation within prior 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Clostridium difficile</keyword>
</DOC>